# reload+after+2024-01-21 11:35:39.219641
address1§Thorp Arch Estate
address2§Unit 20 Ash Way
city§Wetherby
zip§LS23 7FA
country§United Kingdom
phone§44 1904 217 070
website§https://www.avacta.com
industry§Biotechnology
industryKey§biotechnology
industryDisp§Biotechnology
sector§Healthcare
sectorKey§healthcare
sectorDisp§Healthcare
longBusinessSummary§Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
fullTimeEmployees§120
companyOfficers§[{'maxAge': 1, 'name': 'Dr. David Alastair Maclaughlin Smith', 'age': 57, 'title': 'CEO & Executive Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 444000, 'exercisedValue': 0, 'unexercisedValue': 775918}, {'maxAge': 1, 'name': 'Mr. Tony  Gardiner', 'age': 52, 'title': 'CFO, Company Secretary & Executive Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 273000, 'exercisedValue': 0, 'unexercisedValue': 332516}, {'maxAge': 1, 'name': 'Dr. Christina M. Coughlin B.S., M.D., Ph.D.', 'age': 53, 'title': 'Interim Chief Medical Officer & Non-Executive Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 37000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Emma  Wright', 'title': 'Group In-House Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Vinegrad', 'title': 'Group Communications Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Craig  Slater', 'age': 60, 'title': 'Chief Operating Officer of Diagnostics', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 69000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matt  Johnson', 'title': 'Chief Scientific Officer of Diagnostics', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Neil  Bell', 'age': 65, 'title': 'Chief Development Officer of Therapeutics', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Fiona  McLaughlin FSB, Ph.D.', 'age': 53, 'title': 'Chief Scientific Officer of Therapeutics Division', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Wilson', 'title': 'Chief Commercial Officer of Diagnostics', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.324
priceToSalesTrailing12Months§20.618456
currency§GBp
forwardEps§-13.39
exchange§LSE
quoteType§EQUITY
shortName§AVACTA GROUP PLC ORD 10P
longName§Avacta Group Plc
firstTradeDateEpochUtc§1063004400
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§ecc4c9e3-0bff-3b26-a061-e69c84a9a9c2
messageBoardId§finmb_23568713
targetHighPrice§190.0
targetLowPrice§70.0
targetMeanPrice§138.0
targetMedianPrice§154.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§3
quickRatio§0.66
grossMargins§0.47849998
ebitdaMargins§-1.62895
trailingPegRatio§None
